Transdermal delivery of oxybutynin chloride proniosomal gels for the treatment of overactive bladder

References

• Abrams P, Cardozo L, Fall M, et al. (2002). The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neurourol Urodyn 21:167–78
   PubMed Web of Science ®Google Scholar
• Agarwal R, Katare OP, Vyas SP. (2001). Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm 228:43–52
   PubMed Web of Science ®Google Scholar
• Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. (2005). Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm 59:485–90
   PubMed Web of Science ®Google Scholar
• Appell RA. (2002). The newer antimuscarinic drugs: bladder control with less dry mouth. Cleve Clin J Med 69:761–9
   PubMed Web of Science ®Google Scholar
• Arunothayanun P, Bernard MS, Craig DQ, et al. (2000). The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from a hexadecyl diglycerol ether. Int J Pharm 201:7–14
   PubMed Web of Science ®Google Scholar
• Bae J, Park JW. (2015). Formulation and pharmacokinetic evaluation of controlled-release oxybutynin tablets in dogs. Trop J Pharm Res 14:363–9
   Web of Science ®Google Scholar
• Balakrishnan P, Shanmugam S, Lee WS, et al. (2009). Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery. Int J Pharm 377:1–8
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Sand PK, Zinner NR. (2003). Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 62:237–42
   PubMed Web of Science ®Google Scholar
• El-Laithy HM, Shoukry O, Mahran LG. (2011). Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies. Eur J Pharm Biopharm 77:43–55
   PubMed Web of Science ®Google Scholar
• Guinedi AS, Mortada ND, Mansour S, Hathout RM. (2005). Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm 306:71–82
   PubMed Web of Science ®Google Scholar
• Hesch K. (2007). Agents for treatment of overactive bladder: a therapeutic class review. Proc (Bayl Univ Med Cent) 20:307–14
   PubMedGoogle Scholar
• Kennelly MJ. (2010). A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol 12:12–19
   PubMedGoogle Scholar
• Krause P, Fuhr U, Schnitker J, et al. (2013). Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study. J Urol 190:1791–7
   PubMed Web of Science ®Google Scholar
• Kumar GP, Rajeshwarrao P. (2011). Nonionic surfactant vesicular systems for effective drug delivery – an overview. Acta Pharm Sinica B 1:208–19
   Web of Science ®Google Scholar
• Lawrence MJ, Chauhan S, Lawrence SM, Barlow DJ. (1996). The formation, characterization and stability of non-ionic surfactant vesicles. STP Pharm Sci 1:49–60
   Google Scholar
• Liu D, Chen W, Tsai L, Yang S. (2000). Microcalorimetric studies of the effects of cholesterol on the physical stability of liposome. Colloids Surf B Biointerfaces 172:57–67
   Web of Science ®Google Scholar
• Liu T, Guo R, Hua W, Qiu J. (2007). Structure behaviors of hemoglobin in PEG 6000/Tween 80/Span 80/H2O niosome system. Colloids Surf A Physicochem Eng Aspects 293:255–61
   Web of Science ®Google Scholar
• Mohammed AR, Weston N, Coombes AGA, et al. (2004). Liposome formulation of poorly soluble drugs: optimization of drug loading and ESEM analysis of stability. Int J Pharm 285:23–34
   PubMed Web of Science ®Google Scholar
• Nasseri B. (2005). Effect of cholesterol and temperature on the elastic properties of niosomal membranes. Int J Pharm 300:95–101
   PubMed Web of Science ®Google Scholar
• Nimbalkar UA, Dhoka MV, Sonawane PA. (2011). Solid lipid nanoparticles for enhancement of oral bioavailability of cefpodoxime proxetil. Int J Pharm Sci Res 2:2974–82
   Google Scholar
• Nitti VW, Sanders S, Staskin DR, et al. (2006). Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology 67:657–64
   PubMed Web of Science ®Google Scholar
• Oki T, Toma-Okura A, Yamada S. (2006). Advantages for transdermal over oral oxybutynin to treat overactive bladder: muscarinic receptor binding, plasma drug concentration and salivary secretion. J Pharm Exp Ther 316:1137–45
   PubMed Web of Science ®Google Scholar
• Radha GV, Rani TS, Sarvani B. (2013). A review on proniosomal drug delivery system for targeted drug action. J Basic Clin Pharm 4:42–8
   PubMedGoogle Scholar
• Radomski SB, Barkin J. (2012). Medical management of overactive bladder. Can J Urol 19:1–9
   PubMed Web of Science ®Google Scholar
• Rajan R, Khanam J, Nanda A. (2008). Design of a matrix patch formulation for long-acting permeation of diclofenac potassium. Asian J Pharm Sci 3:30–9
   Google Scholar
• Rajan R, Sheba RND, Jasmina K, et al. (2010). Studies on the effect of plasticizer on in vitro release and ex vivo permeation from Eudragit E 100 based chlorpheniramine maleate matrix type transdermal delivery system. J Exc Food Chem 1:3–12
   Google Scholar
• Rawat AS, Kumar MS, Khurana B, Mahadevan N. (2011). Proniosomal gel: a novel topical delivery system. IJAPR 3:1–10
   Google Scholar
• Salvatore S, Soligo M, Proietti F. (2005). Overactive bladder syndrome: considerations in pharmacotherapy and new perspectives. Eur J Obstet Gynecol Reprod Biol 120:129–33
   PubMed Web of Science ®Google Scholar
• Sand P, Zinner N, Newman D. (2007). Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicenter, community-based, randomized study. BJU Int 99:836–44
   PubMed Web of Science ®Google Scholar
• Sandhya P, Mehvash SF, Subrahmanyam CVS. (2013). Enhancement of permeability of losartan potassium by formulating as proniosomal gel. IJBPR 4:743–8
   Google Scholar
• Sarpotdar PP, Zatz JL. (1986). Percutaneous absorption enhancement by non-ionic surfactants. Drug Dev Ind Pharm 12:1625–47
   Web of Science ®Google Scholar
• Sathyan G, Chancellor MB, Gupta SK. (2001). Effect of OROS® controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol 52:409–17
   PubMed Web of Science ®Google Scholar
• Sussman DO. (2007). Overactive bladder: treatment options in primary care medicine. JAOA 107:379–85
   Google Scholar
• Thomas L, Viswanad V. (2012). Formulation and optimization of clotrimazole-loaded proniosomal gel using a 32 factorial design. Sci Pharm 80:731–48
   PubMedGoogle Scholar
• Uchegbu IF, Florence AT. (1995). Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv Colloid Interface Sci 58:1–55
   Web of Science ®Google Scholar
• Uchegbu IF, Schätzlein A, Vanlerberghe G, et al. (1997). Polyhedral Non-ionic Surfactant Vesicles. J Pharm & Pharmacol 49:606–10
   Google Scholar
• Van Der Vaart CH, De Leeuw JRJ, Roovers JPWR, et al. (2002). The effect of urinary incontinence and overactive symptoms on quality of life in young women. BJU Int 90:544–9
   PubMed Web of Science ®Google Scholar
• Vanhal D, Vanrensen A, Devringer T, et al. (1996). Diffusion of estradiol from nonionic surfactant vesicles through human stratum-corneum in vitro. STP Pharm Sci 6:72–8
   Google Scholar
• Zobrist RH, Schmid B, Feick A, et al. (2001). Pharmacokinetics of the R- and S- enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharmacol Res 18:1029–34
   Web of Science ®Google Scholar